Obesema vs Ozempic: Comparison Guide

Obesema vs Ozempic: Comparison Guide

If you are comparing Obesema and Ozempic, the key point is that Obesema is an actual Alkem semaglutide brand in India. It should not be framed as only a loose name that may or may not refer to semaglutide.

This guide compares the two brands in a more practical way so you can verify what has actually been prescribed. Consult your healthcare provider before starting any medication.

What is Ozempic?

Ozempic is Novo Nordisk's brand for semaglutide, a GLP-1 receptor agonist used in adults with type 2 diabetes and widely discussed in weight-management settings.

Ozempic is given as a once-weekly injection.

What is Obesema?

Obesema is an Alkem semaglutide injection brand in India. Alkem's launch materials list Semasize, Obesema, and Hepaglide as semaglutide brands introduced after its launch and approval milestones.

That means Obesema should be treated as a real branded semaglutide option, not an ambiguous product label.

What they have in common

Obesema and Ozempic share the same active ingredient: semaglutide.

That means both are discussed in relation to:

• improved glucose control in type 2 diabetes
• slower gastric emptying
• reduced appetite in many users
• weekly semaglutide dosing under clinician guidance

Key differences: Obesema vs Ozempic

1. Manufacturer

• Ozempic is made by Novo Nordisk.
• Obesema is associated with Alkem in India.

2. Market context

Ozempic is the originator semaglutide brand with global recognition. Obesema is part of the newer India-market semaglutide rollout from a domestic manufacturer.

3. Device and access workflow

Alkem described both disposable and reusable pen options across its semaglutide launch. Ozempic has its own branded pen system. That can affect the day-to-day treatment experience even with the same active ingredient.

4. Evidence base

Large semaglutide studies are still mostly tied to the broader originator evidence base. Clinicians use that evidence when discussing Obesema while also checking local brand details and approval context.

Side effects and safety

Because both are semaglutide-based, the expected side-effect profile is broadly similar. Common effects may include:

• nausea
• vomiting
• diarrhoea
• constipation
• abdominal discomfort
• lower appetite

Bottom line

Obesema and Ozempic are both semaglutide injection brands. The real comparison is brand, manufacturer, device, and access—Alkem's Obesema in India versus Novo Nordisk's Ozempic—not a clear brand versus an uncertain label.

Your clinician can help you compare dosing, refill reliability, and device workflow safely. Consult your healthcare provider before starting any medication.

Sources

• https://admin.alkemlabs.com/uploads/Press_Release_Alkem_Semaglutide_Day_1_launch_final_fc1e90e3be.pdf
• https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl.pdf
• https://cdsco.gov.in/opencms/opencms/en/Home/
• https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
• https://medlineplus.gov/druginfo/meds/a618008.html